{
    "nct_id": "NCT05067140",
    "official_title": "A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer",
    "inclusion_criteria": "Part A,B,C and D:\n\n* Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate.\n* Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nPart A:\n\n* Progression on at least 2 prior approved systemic therapies for metastatic prostate cancer (at least one must be a second-generation androgen inhibitor, e.g., abiraterone, enzalutamide, darolutamide, apalutamide).\n* Progressive mCRPC\n\nPart B:\n\n* Participants must have received at least one but no more than three prior second generation anti-androgen agents (e.g., enzalutamide or abiraterone).\n* Participants must have received no more than two prior chemotherapy regimens.\n* Progressive mCRPC\n\nPart C & D:\n\n• Metastatic castration resistant or sensitive prostate cancer with radiographic evidence of metastatic disease\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Part A and B:\n\n* Known symptomatic brain metastases requiring steroids (above physiologic replacement doses).\n* Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery.\n* Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow.\n* Receipt of an investigational drug(s) within 4 weeks prior to anticipated first dose\n* Systemic anti-cancer therapy within 2 weeks of first dose of study drug (except agents to maintain castrate status). For bicalutamide, mitomycin C, or nitrosoureas the exclusion period must be 6 weeks and for abiraterone 4 weeks.\n\nPart C and D\n\n• Prior treatment with a second generation NHA",
    "miscellaneous_criteria": ""
}